^
Association details:
| Biomarker: | CTLA4 overexpression |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Yondelis (trabectedin) (Alkylating agent, DNA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study.
Published date:
05/13/2020
Excerpt:
Selection criteria included patients with STS...High expression of CD274 (PD-L1) was significantly associated with better PFS of trabectedin (5.4 vs. 3.0 months; p= 0.006)…. Similar results were obtained with high expression of CTLA4 and LAG3: 6.0 vs 3.1 months; p = 0.005 and 5.4 vs 2.7 months; p = 0.042, respectively.
DOI:
10.1200/JCO.2020.38.15_suppl.11546
